<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="10" family="Minion" color="#231f20"/>
	<fontspec id="1" size="10" family="Minion" color="#000000"/>
	<fontspec id="2" size="10" family="MinionExp" color="#231f20"/>
	<fontspec id="3" size="7" family="Minion" color="#231f20"/>
	<fontspec id="4" size="12" family="Minion-Black" color="#231f20"/>
	<fontspec id="5" size="10" family="Minion" color="#231f20"/>
<text top="45" left="51" width="5" height="9" font="0">2</text>
<text top="45" left="486" width="63" height="9" font="0">ISRN Oncology</text>
<text top="74" left="51" width="240" height="9" font="0">accurately delivered with steep dose gradients and lower</text>
<text top="85" left="51" width="240" height="9" font="0">doses to areas deemed to be at lower risk and minimal dose</text>
<text top="97" left="51" width="240" height="9" font="0">to other organs. The ability of IMRT to deliver doses with a</text>
<text top="108" left="51" width="240" height="9" font="0">high degree of conformality has led to interest in the use of</text>
<text top="119" left="51" width="240" height="9" font="0">IMRT to successfully eliminate sites of tumour involvement</text>
<text top="131" left="51" width="126" height="9" font="0">whilst sparing normal tissues <a href="">[</a></text>
<text top="131" left="177" width="10" height="9" font="1"><a href="">10</a></text>
<text top="131" left="186" width="2" height="9" font="0">,</text>
<text top="131" left="192" width="10" height="9" font="1"><a href="">11</a></text>
<text top="131" left="202" width="89" height="9" font="0"><a href="">]. </a>Appropriate patient</text>
<text top="142" left="51" width="240" height="9" font="0">selection and accurate target definition are critical to the</text>
<text top="153" left="51" width="240" height="9" font="0">success of attempts to spare normal tissues, with the potential</text>
<text top="165" left="51" width="240" height="9" font="0">for the risk of increased nodal recurrence associated with</text>
<text top="176" left="51" width="156" height="9" font="0">the steep dose gradients in IMRT <a href="">[</a></text>
<text top="176" left="207" width="10" height="9" font="1"><a href="">12</a></text>
<text top="176" left="216" width="75" height="9" font="0">]. Indeed, quality</text>
<text top="188" left="51" width="240" height="9" font="0">of radiotherapy has been identified as a major factor in</text>
<text top="199" left="51" width="240" height="9" font="0">determining outcome of nonsurgical treatment for HNSCC</text>
<text top="210" left="51" width="4" height="9" font="0"><a href="">[</a></text>
<text top="210" left="54" width="10" height="9" font="1"><a href="">13</a></text>
<text top="210" left="64" width="227" height="9" font="0"><a href="">]. </a>Reliable localisation of sites of tumour involvement</text>
<text top="222" left="51" width="240" height="9" font="0">is essential to the success of treatment protocols aimed at</text>
<text top="233" left="51" width="106" height="9" font="0">limiting late tissue toxicity.</text>
<text top="244" left="66" width="202" height="9" font="0">The radiation oncologist frequently has to make di</text>
<text top="242" left="268" width="8" height="13" font="2">ﬃ</text>
<text top="244" left="276" width="15" height="9" font="0">cult</text>
<text top="256" left="51" width="240" height="9" font="0">judgements based on anatomical imaging to include or</text>
<text top="267" left="51" width="240" height="9" font="0">otherwise equivocal lymph nodes in the high-dose target</text>
<text top="279" left="51" width="164" height="9" font="0">volume. Functional imaging techniques o</text>
<text top="276" left="215" width="6" height="13" font="2">ﬀ</text>
<text top="279" left="221" width="70" height="9" font="0">er the potential to</text>
<text top="290" left="51" width="240" height="9" font="0">provide complementary information to anatomical imaging</text>
<text top="301" left="51" width="170" height="9" font="0">with CT and MRI to aid in these decisions.</text>
<text top="300" left="223" width="7" height="7" font="3">18</text>
<text top="301" left="230" width="61" height="9" font="0">Fluoride-fluor-</text>
<text top="313" left="51" width="240" height="9" font="0">odeoxyglucose positron emission tomography (FDG PET)</text>
<text top="324" left="51" width="240" height="9" font="0">is a widely used functional imaging technique in oncology.</text>
<text top="335" left="51" width="95" height="9" font="0">Tumour cells exhibit di</text>
<text top="333" left="146" width="6" height="13" font="2">ﬀ</text>
<text top="335" left="151" width="140" height="9" font="0">erential glucose uptake (the “War-</text>
<text top="347" left="51" width="26" height="9" font="0">burg e</text>
<text top="344" left="77" width="6" height="13" font="2">ﬀ</text>
<text top="347" left="83" width="193" height="9" font="0">ect”) as a basis of the identification of cancer <a href="">[</a></text>
<text top="347" left="275" width="10" height="9" font="1"><a href="">14</a></text>
<text top="347" left="285" width="6" height="9" font="0"><a href="">].</a></text>
<text top="358" left="51" width="240" height="9" font="0">Increased glucose uptake by nonmalignant tissue, common-</text>
<text top="369" left="51" width="240" height="9" font="0">ly in the presence of infection or inflammation, leads to</text>
<text top="381" left="51" width="240" height="9" font="0">false positive results. Integrated PET-CT, which combines the</text>
<text top="392" left="51" width="240" height="9" font="0">complementary techniques of PET and CT in a single study,</text>
<text top="404" left="51" width="5" height="9" font="0">o</text>
<text top="401" left="56" width="6" height="13" font="2">ﬀ</text>
<text top="404" left="62" width="229" height="9" font="0">ers the potential to improve upon the inherent size limita-</text>
<text top="415" left="51" width="240" height="9" font="0">tions in terms of accurate lymph node identification with</text>
<text top="426" left="51" width="240" height="9" font="0">MRI and CT, not being limited by formal size criteria</text>
<text top="438" left="51" width="4" height="9" font="0"><a href="">[</a></text>
<text top="438" left="54" width="10" height="9" font="1"><a href="">15</a></text>
<text top="438" left="64" width="227" height="9" font="0"><a href="">]. </a>Limitations of PET include issues with regard to scan-</text>
<text top="449" left="51" width="125" height="9" font="0">ner resolution, partial volume e</text>
<text top="447" left="176" width="6" height="13" font="2">ﬀ</text>
<text top="449" left="182" width="109" height="9" font="0">ects, and the need for accu-</text>
<text top="460" left="51" width="240" height="9" font="0">rate coregistration with the CT scan. FDG PET-CT imag-</text>
<text top="472" left="51" width="240" height="9" font="0">ing in HNSCC has multiple potential applications including</text>
<text top="483" left="51" width="240" height="9" font="0">staging, radiotherapy planning, treatment adaptation, res-</text>
<text top="495" left="51" width="182" height="9" font="0">ponse assessment, and recurrence detection <a href="">[</a></text>
<text top="495" left="232" width="5" height="9" font="1"><a href="">9</a></text>
<text top="495" left="237" width="2" height="9" font="0">,</text>
<text top="495" left="242" width="10" height="9" font="1"><a href="">15</a></text>
<text top="495" left="252" width="2" height="9" font="0"><a href="">,</a></text>
<text top="495" left="257" width="10" height="9" font="1"><a href="">16</a></text>
<text top="495" left="267" width="24" height="9" font="0"><a href="">]. </a>The</text>
<text top="506" left="51" width="240" height="9" font="0">site of recurrence has been shown to correlate with the base-</text>
<text top="517" left="51" width="127" height="9" font="0">line sites of FDG-avid disease <a href="">[</a></text>
<text top="517" left="178" width="10" height="9" font="1"><a href="">17</a></text>
<text top="517" left="187" width="103" height="9" font="0">]. FDG PET-CT has been</text>
<text top="529" left="51" width="240" height="9" font="0">demonstrated to be able to identify metastatic head and neck</text>
<text top="540" left="51" width="240" height="9" font="0">malignancy in cases where MRI and CT fail to demonstrate</text>
<text top="551" left="51" width="33" height="9" font="0">disease <a href="">[</a></text>
<text top="551" left="84" width="10" height="9" font="1"><a href="">18</a></text>
<text top="551" left="94" width="2" height="9" font="0"><a href="">,</a></text>
<text top="551" left="98" width="10" height="9" font="1"><a href="">19</a></text>
<text top="551" left="108" width="183" height="9" font="0">]. The use of FDG PET-CT for staging HNSCC</text>
<text top="563" left="51" width="240" height="9" font="0">(other than in the setting of cervical lymph node metastases</text>
<text top="574" left="51" width="240" height="9" font="0">of unknown primary origin) remains controversial, with</text>
<text top="585" left="51" width="240" height="9" font="0">some authorities not recommending its use in routine stag-</text>
<text top="597" left="51" width="20" height="9" font="0">ing <a href="">[</a></text>
<text top="597" left="70" width="5" height="9" font="1"><a href="">9</a></text>
<text top="597" left="75" width="216" height="9" font="0">], whilst others support the role of FDG PET-CT for</text>
<text top="608" left="51" width="168" height="9" font="0">staging locoregional and distant disease <a href="">[</a></text>
<text top="608" left="219" width="10" height="9" font="1"><a href="">20</a></text>
<text top="608" left="228" width="63" height="9" font="0">]. Some studies</text>
<text top="620" left="51" width="240" height="9" font="0">have suggested that the addition of FDG PET-CT to con-</text>
<text top="631" left="51" width="240" height="9" font="0">ventional staging methods improves the accuracy of nodal</text>
<text top="642" left="51" width="50" height="9" font="0">assessment <a href="">[</a></text>
<text top="642" left="100" width="10" height="9" font="1"><a href="">21</a></text>
<text top="642" left="110" width="5" height="9" font="0"><a href="">–</a></text>
<text top="642" left="115" width="10" height="9" font="1"><a href="">23</a></text>
<text top="642" left="124" width="166" height="9" font="0">]. At the heart of any debate regarding the</text>
<text top="654" left="51" width="240" height="9" font="0">utility of FDG PET-CT in addition to conventional anato-</text>
<text top="665" left="51" width="240" height="9" font="0">mical imaging is the assessment of the potential impact of the</text>
<text top="676" left="51" width="240" height="9" font="0">investigation upon patient management. This impact may</text>
<text top="688" left="51" width="240" height="9" font="0">vary depending upon the patient population, tumour stage,</text>
<text top="699" left="51" width="142" height="9" font="0">and treatment under consideration.</text>
<text top="710" left="66" width="225" height="9" font="0">The aim of this study was to assess the utility of FDG</text>
<text top="722" left="51" width="240" height="9" font="0">PET-CT as an adjunct to conventional staging methods</text>
<text top="733" left="51" width="240" height="9" font="0">in patients with locally advanced HNSCC due to undergo</text>
<text top="74" left="309" width="240" height="9" font="0">primary nonsurgical treatment. The value of FDG PET-CT</text>
<text top="85" left="309" width="240" height="9" font="0">on identification of levels of nodal involvement was deter-</text>
<text top="97" left="309" width="240" height="9" font="0">mined to assess whether FDG PET-CT can influence process</text>
<text top="108" left="309" width="172" height="9" font="0">of defining the radiotherapy target volume.</text>
<text top="135" left="309" width="56" height="11" font="4"><b>2. Methods</b></text>
<text top="156" left="309" width="240" height="9" font="5"><i>2.1. Inclusion Criteria. </i>Formal institutional review board ap-</text>
<text top="168" left="309" width="240" height="9" font="0">proval was waived for this retrospective study. Consecutive</text>
<text top="179" left="309" width="240" height="9" font="0">patients between August 2008 and April 2011 who under-</text>
<text top="190" left="309" width="240" height="9" font="0">went a FDG PET-CT scan for head and neck cancer were</text>
<text top="202" left="309" width="240" height="9" font="0">obtained from an institutional database. Electronic case</text>
<text top="213" left="309" width="240" height="9" font="0">notes were used to identify patients who fulfilled the eligibi-</text>
<text top="225" left="309" width="98" height="9" font="0">lity criteria for the study.</text>
<text top="236" left="324" width="207" height="9" font="0">Eligible patients fulfilled all of the following criteria.</text>
<text top="257" left="323" width="225" height="9" font="0">(1) Histologically confirmed squamous cell carcinoma of</text>
<text top="268" left="339" width="210" height="9" font="0">the oropharynx, oral cavity, hypopharynx, larynx, or</text>
<text top="280" left="339" width="71" height="9" font="0">paranasal sinuses.</text>
<text top="297" left="323" width="164" height="9" font="0">(2) Nasopharyngeal cancer was excluded.</text>
<text top="313" left="323" width="225" height="9" font="0">(3) Reviewed by specialist head and neck multidisciplin-</text>
<text top="325" left="339" width="50" height="9" font="0">ary meeting.</text>
<text top="342" left="323" width="207" height="9" font="0">(4) TNM stage III or IV prior to FDG PET-CT scan.</text>
<text top="359" left="323" width="225" height="9" font="0">(5) Decision made prior to FDG PET-CT to proceed with</text>
<text top="370" left="339" width="210" height="9" font="0">radical nonsurgical treatment (radiotherapy alone or</text>
<text top="381" left="339" width="84" height="9" font="0">chemoradiotherapy).</text>
<text top="398" left="323" width="225" height="9" font="0">(6) FDG PET-CT performed prior to commencement of</text>
<text top="410" left="339" width="210" height="9" font="0">treatment for staging and/or as a baseline for future</text>
<text top="421" left="339" width="83" height="9" font="0">response assessment.</text>
<text top="442" left="309" width="240" height="9" font="0">Baseline demographics were obtained from review of elec-</text>
<text top="453" left="309" width="206" height="9" font="0">tronic case notes (Patient Pathway Manager, Leeds).</text>
<text top="480" left="309" width="240" height="9" font="5"><i>2.2. Staging. </i>Conventional staging of locally advanced</text>
<text top="491" left="309" width="240" height="9" font="0">HNSCC was routinely performed by physical examination</text>
<text top="502" left="309" width="240" height="9" font="0">and neck palpation, fiberoptic endoscopy, examination un-</text>
<text top="514" left="309" width="240" height="9" font="0">der anaesthetic with biopsy where indicated, MRI or contra-</text>
<text top="525" left="309" width="240" height="9" font="0">st-enhanced CT of head and neck region depending upon</text>
<text top="537" left="309" width="240" height="9" font="0">local protocols, and CT of the thorax. Results were routinely</text>
<text top="548" left="309" width="240" height="9" font="0">reviewed in a specialist head and neck MDT meeting and a</text>
<text top="559" left="309" width="240" height="9" font="0">TNM classification, based on all available clinical and radio-</text>
<text top="571" left="309" width="240" height="9" font="0">logical data, according to the American Joint Committee on</text>
<text top="582" left="309" width="240" height="9" font="0">Cancer TNM staging was assigned prior to the FDG PET-CT</text>
<text top="593" left="309" width="24" height="9" font="0">scan <a href="">[</a></text>
<text top="593" left="332" width="10" height="9" font="1"><a href="">24</a></text>
<text top="593" left="342" width="207" height="9" font="0">]. The method of conventional crosssectional imag-</text>
<text top="605" left="309" width="228" height="9" font="0">ing used for staging was recorded from radiology records.</text>
<text top="631" left="309" width="240" height="9" font="5"><i>2.3. CT Protocol. </i>Contrast-enhanced CT was most com-</text>
<text top="643" left="309" width="240" height="9" font="0">monly performed at our institution after referral from the re-</text>
<text top="654" left="309" width="240" height="9" font="0">gional oncology team on a 64-slice CT (Siemens Sensation,</text>
<text top="665" left="309" width="240" height="9" font="0">Siemens Healthcare, Erlangen, Germany) using a contiguous</text>
<text top="677" left="309" width="240" height="9" font="0">1 mm reconstruction following a bolus of 100 mL of iodi-</text>
<text top="688" left="309" width="240" height="9" font="0">nated contrast or a 16-slice CT (Siemens 16, Siemens Health-</text>
<text top="699" left="309" width="240" height="9" font="0">care) using the same acquisition parameters. The remaining</text>
<text top="711" left="309" width="240" height="9" font="0">contrast-enhanced CT scans were acquired at one of several</text>
<text top="722" left="309" width="240" height="9" font="0">referring hospitals on multislice CT systems using similar ac-</text>
<text top="733" left="309" width="85" height="9" font="0">quisition parameters.</text>
</page>
</pdf2xml>
